A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pegylated Interferon alpha-2a and Ribavirin in Treatment-Naive Adults with Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE I)

Trial Profile

A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pegylated Interferon alpha-2a and Ribavirin in Treatment-Naive Adults with Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE I)

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Peginterferon alfa-2a; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms MALACHITE I
  • Sponsors AbbVie
  • Most Recent Events

    • 17 Apr 2016 Results of post-hoc, pooled analysis of 5 studies (TURQUOISE-III, PEARL-II, PEARL-III, TOPAZ-II and MALACHITE-I) presented at The International Liver Congress™ 2016
    • 21 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 May 2015 Data from this trial will be presented at Digestive Disease Week 2015, according to an AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top